CD274 and head and neck squamous cell carcinoma: Inhibition of the PD-1/PD-L1 axis with or without chemotherapy has been shown to improve overall survival (OS) in first-line treatment of PD-L1-expressing recurrent/metastatic HNSCC as compared to the chemotherapy plus cetuximab-based EXTREME regimen (Burtness et al. 2019).